osimertinib mesylate  (MedChemExpress)

Journal: Oncogene

Article Title: RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1.

doi: 10.1038/s41388-024-03220-z

Figure Lengend Snippet: Fig. 2 Elevated RBM15 expression in patients with LUAD with EGFR mutations correlates with adverse outcomes. A, B Representative image of IHC staining and IHC scores of RBM15 from EGFR wild-type (WT) or mutant patients. Mann–Whitney test. C, D Immunofluorescence of RBM15 protein expression in LUAD PDO with or without EGFR mutations (scale bar: 50 μm). T test. E OS in TCGA LUAD cases with EGFR mutation according to RBM15 expression. F PFS after initiation of osimertinib treatment in patients with EGFR mutations expressing high vs. low RBM15 mRNA levels. G, H Osimertinib IC50 value of HCC827 and H1975 cells transfected with NC and RBM15-OE. T test. Error bars represent the means ± SDs. *P < 0.05, ****P < 0.0001.

Article Snippet: When the tumors reached a longitudinal diameter of 5 mm, the mice were randomly assigned to each group and subsequently treated orally with an equal volume of osimertinib mesylate (Selleck, S5078, TX, 20 mg/kg/day) or corn oil by gavage every 2 days.

Techniques: Expressing, Immunohistochemistry, Mutagenesis, MANN-WHITNEY, Transfection

Journal: Oncogene

Article Title: RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1.

doi: 10.1038/s41388-024-03220-z

Figure Lengend Snippet: Fig. 6 EMT induction and RBM15 upregulation as precursors to osimertinib resistance development. A H1975 cells were exposed to 1 μm osimertinib and cultured for 20 days to select H1975-DTP cells (top panel). H1975 and H1975-DTP cells were incubated with osimertinib for 48 h, cell viability was measured using the CCK-8 assay, and the IC50 was calculated (bottom panel). T test. B Western blot investigation of EGFR, ERK, and AKT protein levels and their phosphorylation. C Western blot assessment of RBM15 protein expression levels in H1975 and H1975-DTPCs. D, E Western blot and immunofluorescence assessment of EMT marker proteins in H1975 and H1975-DTP cells (scale bar: 50 μm). T test. F A model diagram demonstrating that RBM15 suppresses SPOCK1 mRNA expression through m6A modification, enhancing EMT-mediated osimertinib resistance in refractory tumors. This figure was created using the BioRender website (https:// biorender.com). Error bars represent the means ± SDs. ***P < 0.001, ****P < 0.0001.

Article Snippet: When the tumors reached a longitudinal diameter of 5 mm, the mice were randomly assigned to each group and subsequently treated orally with an equal volume of osimertinib mesylate (Selleck, S5078, TX, 20 mg/kg/day) or corn oil by gavage every 2 days.

Techniques: Cell Culture, Incubation, CCK-8 Assay, Western Blot, Phospho-proteomics, Expressing, Marker

Journal: Molecules

Article Title: Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy

doi: 10.3390/molecules29071448

Figure Lengend Snippet: Small-molecule EGFR inhibitors for cancer therapy a .

Article Snippet: 10 , Osimertinib mesylate , AstraZeneca (London, UK) , NSCLC , EGFR; HER2; HER3; HER4; EGFR T790M; EGFR L858R; EGFR 19del; , Approved (2015).

Techniques:

Journal: Molecules

Article Title: Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy

doi: 10.3390/molecules29071448

Figure Lengend Snippet: Synthesis of osimertinib mesylate.

Article Snippet: 10 , Osimertinib mesylate , AstraZeneca (London, UK) , NSCLC , EGFR; HER2; HER3; HER4; EGFR T790M; EGFR L858R; EGFR 19del; , Approved (2015).

Techniques: